High affinity benzodiazepine binding sites have been described in brain, and intensive study of their properties has led to the hypothesis that the major actions of the benzodiazepines may be mediated through interactions with GABA-ergic neuronal mechanisms (Costa and Guidotti, 1979; Tallman et al., 1980; Haefely et al., 1981) . These interactions seem to be allosteric between one of the GABA receptors (Browner et al., 1981) and the high affinity binding site for the benzodiazepines (Tallman et al., 1978; Massotti et al., 1981) . A third component of this system is a site closely related to a channel for anions; it has been studied by examining the binding of picrotoxinin (Leeb-Lundberg and Olsen, 1980) and seems to be the site of action of several other compounds capable of interacting with the benzodiazepines (Williams and Risley, 1979) .
Previously, we (Yousufi et al., 1979) and others (Gavish et al., 1979; Lang et al., 1979) have solubilized the benzodiazepine binding site from brain; in the course of these studies, the ability to photolabel this binding site (Mohler et al., 1980) was exploited to study the properties of the active binding site. When membrane preparations were studied, several sites were inactivated for each site labeled (Mohler et al., 1980; Thomas and Tallman, 1981) ; in soluble preparations, as many sites were inactivated as labeled (Thomas and Tallman, 1981) . Among the possible explanations for these data, conversion of the ' To whom correspondence should be addressed at NIMH, Building 10, Room 3N256,9000
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?ligh affinity binding sites for the benzodiazepines to a low affinity form was discussed (Thomas and Tallman, 1981) .
To examine this possibility, binding to the benzodiazepine site was carried out with the radiolabeled antagonists ethyl-/I-carboline-3-carboxylate (Nielsen et al., 1981; Nielson, 1981), CGS 8216 (Czernik et al., 1982) , and Ro 15-1788 (Hunkeler et al., 1981; Mohler and Richards, 1981) . Binding of these antagonists was not altered by photolabeling; however, the ability of benzodiazepines to displace antagonist binding was altered with competition curves shifted to the right. These results are consistent with photolabeling converting a homogeneous set of benzodiazepine binding sites into two subsites of high and low affinity.
Materials and Methods
Reagents were purchased or prepared essentially as previously described (Thomas and Tallman, 1981) , with the following additions.
[3H]Ethyl-P-carboline-3-carboxylate Sp. Act. 80 .6 Ci/mmol) was obtained from New England Nuclear. The nonspecific binding obtained with this lot of ligand was less than 15% of the total binding for a ligand concentration of 1 nM. ["HI P-Carboline solutions were prepared fresh daily from the ethanol stock solution due to concern for the stability of this compound's ester linkage. (Thomas and Tallman, 1981) . Forebrain tissue containing cortical, hippocampal, and striatal brain regions (Glowinski and Iversen, 1966) was used in all studies. Control membranes were prepared in a manner which was identical to the photolabeled membranes (exposed to ultraviolet light, [3H]flunitrazepam, and washing) except for the inclusion of 10m5 M lorazepam, which blocks photolabeling. Untreated membranes were not subjected to ultraviolet light or extensive washing. Since earlier unpublished results had shown no alteration in binding to homogenates that had been frozen, tissue homogenates were routinely prepared in large batches and frozen in aliquots, so that both displacement studies and Scatchard analyses could be performed on identical forebrain tissue preparations. The findings reported here have been observed in three or more separate tissue preparations.
Binding assays were performed as previously described (Tallman et al., 1978) , with the following minor modifications. Samples were incubated for 1 hr, and incubations were terminated quickly by adding 6.5 ml of ice-cold Tris-HCl (pH 7.5 at 5°C) to the incubation mixture. The diluted incubation mixture was immediately filtered, and the filter was washed twice with 6. To resolve this paradox, the ability of a series of benzodiazepines to displace [3H]ethyl-Bcarboline-3-carboxylate binding was investigated. As previously published (Nielsen et al., 1981; Braestrup and Nielsen, 1981) , the benzodiazepines are capable of displacing [3H]ethyl-/?-carboline binding from untreated brain membranes (Fig. 2) . In general, displacement is monophasic in forebrain and consistent with the interpretation that the compounds interact with the same site. Following photolabeling in the presence of flunitrazepam, the displacement curve is shifted to the right and flattened consistent with the interpretation that the compounds interact with more than one set of binding sites (Fig. 2 ). In control membranes in which photolabeling was mostly blocked with lorazepam, but exposed to ultraviolet light in the presence of flunitrazepam, only a slight shift was noted (Fig. 2 ). In addition, no shift in the displacement curve was observed in membranes exposed to ultraviolet light in the absence of flunitrazepam or exposed to ultraviolet light in the presence of lorazepam (data not shown).
A similar right shift and flattening of the displacement curves for several other benzodiazepines was noted (Table II) , indicating a consistent change in the benzodiazepine site with photolabeling. In contrast, as expected from the saturation data shown (Fig. I) , only slight differences were noted in the ability of various antagonists to displace bound [3H]ethyl-P-carboline-3-carboxylate. Compounds tested include ethyl-/3-carboline-3-carboxylate and two analogs, CGS 8216 and its 4-fluorophenyl analog, CGS 9896, and Ro 15-1788 (Table II; Fig. 3).
Results
As we have previously indicated (Thomas and Tallman, 1981) ) photolabeling of benzodiazepine binding sites in the membrane with flunitrazepam results in the inactivation of more sites than the number of sites labeled ( Fig. 1A ; Table I ). Inhibition is noncompetitive in nature.
The Hill coefficients for the inhibition of [3H]ethyl-/?-carboline-3-carboxylate binding by benzodiazepines reflect the changes seen in the displacement curves (Table  II) . The coefficients for benzodiazepines inhibiting binding to photolabeling membranes range from 0.50 to 0.63, whereas in control membranes the values are near unity (range: 0.83 to 0.95). In contrast, the Hill coefficients for the inhibition of /?-carboline binding by various antagonists were similar and near unity in both control and photolabeled membranes. Hill coefficients in the forebrain less than one were obtained for CL 218,872, in agreement with earlier published data (Lippa et al., 1979) ; they were not altered by photolabeling. In an identical preparation from cerebellum, Hill coefficients near unity were observed for both control and photolabeled mem- To determine if the shifts seen in the competition curves for benzodiazepine inhibition of /3-carboline binding could be demonstrated with other radiolabeled antagonists, the binding of [3H]CGS 8216 was also investigated. The displacement data obtained are in agreement with those obtained for j?-carboline binding ( Fig. 1 (Fig. 5 ) of a high affinity binding site for the necessity of using extraordinarily high concentrations the benzodiazepines into a much lower affinity state by of radiolabeled benzodiazepine of high enough specific photolabeling. Since most receptor binding studies, for activity to detect a low affinity, low capacity site. The only report directly measuring possible low affinity ben- 438 Thomas and Tallman Vol. 3, No. 2, Feb. 1983 , """I """I r I"'!" displace binding of any of the labeled antagonists in a range comparable to the centrally active benzodiazepines which all potently displace antagonist binding (Thomas and Tallman, unpublished) . We have also indicated elsewhere that peripheral sites are not photolabeled (Thomas and Tallman, 1981) . Instead, since the binding of several antagonists was not significantly altered by photolabeling (~10%) and, under basal conditions, is potently displaced by benzodiazepines, the ability of a number of benzodiazepines to displace binding of these antagonists was studied. Under the conditions described here, the ability of benzodiazepines to displace antagonist binding was universally shifted to the right and the displacement curves were flattened (Hill coefficients < l), consistent with interaction with more than one site. The Hill coefficients less than one obtained for CGS 8216 binding to control membranes may be related to the mixed type of inhibition reported previously by Czernik et al. (1982) . This also is consistent with the ability of CGS 8216, but not Ro 15-1788, to block pentobarbital's behavioral effects (P. Skolnick, personal communication).
The binding site for the antagonists does not seem to be altered by photolabeling (as measured by direct binding assay or displacement). Similarly, Hirsch et al (1982) have indicated that that propyl-/?-carboline ester binding was relatively unaffected by photolabeling; in contrast, Mohler (1982) has found that Ro 15-1788 binding was decreased by photolabeling. In our preparation, little decrease has been found with any of the three chemically diverse ligands studied; in no case was it statistically significant or at all close to 25% (which is the number of sites labeled). The antagonist binding site is, therefore, not identical to the site which is photolabeled by flunitrazepam. Additionally, from displacement studies with reversibly inhibiting benzodiazepines, we can surmise that the site to which the antagonists bind is closely related to the benzodiazepine binding site, but additional constraints on binding of benzodiazepines exist. It is reasonable to hypothesize that the P-carboline and benzodiazepine sites overlap in some but not all of their steric requirements for binding and that the site which is photolabeled may be separate from both of the reversible binding sites. On the other hand, each photolabeled site seems to be quite intimately related to more than one benzodiazepine site (more sites inactivated than labeled) and can affect binding to these sites in a complicated fashion (perhaps due to site-to-site interactions). The data presented here are consistent with current thinking about interactions of "agonists" (benzodiazepine-like) and "antagonists" (benzodiazepine-against) with the binding site. The binding of "agonists" is enhanced by allosteric interactions with the GABA receptor (Tallman et al., 1980) , whereas binding of the antagonists, methyl-, ethyl-, and propyl-P-carboline-3-carboxylate, is much less enhanced and in some cases inhibited by GABA (Braestrup et al., 1982) . An imidazodiazepine Ro 15-1788, the so-called "selective benzodiazepine antagonist" (Hunkeler et al., 1981;  Mohler and Richards, I%Ij, in our experimental paradigm behaves as a P-carboline, and its binding, similar to the P-carbolines, is not altered by GABA. Similarly, a third putative antagonist, CGS-8216, is not altered either by photolabeling or GABA (Lippa et al., 1979) . This compound has been proposed to distinguish between receptor subtypes on the basis of Hill coefficients < 1 and by its apparent ability to block photolabeling of one of the forms of benzodiazepine binding site (Sieghart and Karobath, 1980) . In our paradigm it does not behave identically to the benzodiazepines and, therefore, may possess novel pharmacological effects. The binding of the radioactive analog of this compound is altered by GABA, and this provides further insight into the nature of its interaction with the binding site (Niehoff et al., 1982) . A compound with similar reported behavioral properties is CGS-9896 (Yokoyama et al., 1982) , and other members of this class may be quite interesting potential anxiolytics (for simplicity's sake, they might be classified as partial agonists or antagonists). However, they do not seem to be efficiently distinguished from antagonists in our paradigm; GABA enhances their binding; however, a small GABA effect has also been noted for propyl-P-carboline ester, an antagonist (Hirsch et al., 1982) .
A more far-reaching implication of this study is the ability under some circumstances to convert high affinity to lower affinity benzodiazepine sites. Several studies have indicated that "cryptic" benzodiazepine binding sites are present in brain and that by either physiological stress (Paul and Skolnick, 1978) or pharmacological manipulation in uiuo (Gallager et al., 1980) and in vitro (Skolnick et al., 1980) these sites are exposed. Although the low affinity sites seen in the present study were created by an irreversible process which does not occur under physiological conditions, it is possible that the low affinity sites described here may be related to the "cryptic" sites described and that the low affinity state is of functional importance. Experiments to examine this possibility are underway.
Finally, the ability to alter the proportion of high affinity and low affinity benzodiazepine sites separately from P-carboline sites may be related to heterogeneity described for the benzodiazepine binding site. It is possible that there may be regional or species differences in these high and low affinity sites, and this can be studied by displacement studies of P-carboline binding following regional photolabeling. It is also possible that heterogenity in the GABA receptor/benzodiazepine binding site/ ionophore complex or occupancy of one or more components with endogenous ligands or drugs may affect the ease of these conformational transitions.
